High mortality from neo-adjuvant chemo-radiotherapy for rectal cancer needs to be evaluated against the alternative of adjuvant therapy

Comment

S Papagrigoriadis. Br J Cancer. 2006.

. 2006 Oct 9;95(7):950; author reply 951-2.

doi: 10.1038/sj.bjc.6603338.

No abstract available

Comment on

Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
Chau I, Brown G, Cunningham D, Tait D, Wotherspoon A, Norman AR, Tebbutt N, Hill M, Ross PJ, Massey A, Oates J. Chau I, et al. J Clin Oncol. 2006 Feb 1;24(4):668-74. doi: 10.1200/JCO.2005.04.4875. J Clin Oncol. 2006. PMID: 16446339 Clinical Trial.
Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study.
Klautke G, Küchenmeister U, Foitzik T, Ludwig K, Prall F, Klar E, Fietkau R. Klautke G, et al. Br J Cancer. 2006 Apr 10;94(7):976-81. doi: 10.1038/sj.bjc.6603053. Br J Cancer. 2006. PMID: 16552435 Free PMC article. Clinical Trial.

1. Chau I, Brown G, Cunningham D, Tait D, Wotherspoon A, Norman AR, Tebbutt N, Hill M, Ross PJ, Massey A, Oates J (2006) Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 24: 668–674 - PubMed
1. Klautke G, Kuchenmeister U, Foitzik T, Ludwig K, Prall F, Klar E, Fietkau R (2006) Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study. Br J Cancer 94: 976–981 - PMC - PubMed